Patient and Physician Perspectives on Multiple Myeloma Data Presented at ASCO and EHA 2025: A Podcast

In this plain language podcast, highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 are discussed, supplemented with additional reflections from the European Hematology Association (EHA) 2025 Congress. These insights come from the perspective of an expert patient and physician, both of whom have experience and expertise in the field of multiple myeloma (MM). This podcast is intended to broaden the reach of complex data on MM from these scientific meetings to a broader audience, including nonspecialists, helping enable better informed treatment decisions between patients and healthcare professionals. Four key topics are discussed, including emerging measurable residual disease (MRD)-driven strategies, novel immunotherapies, supportive care, and precision medicine approaches. MRD negativity is becoming a therapeutic goal and monitoring benchmark in the era of novel immunotherapies, helping patients with MM to achieve long-term disease control and remission. Supportive care, including access to patient organization information and support, is a critical component of modern MM care to maximize treatment benefit and quality of life for patients while limiting treatment toxicities. Finally, personalized treatment approaches and the use of artificial intelligence could re-shape outcomes for patients, including those with high-risk smoldering MM who would benefit from early intervention. As the treatment landscape continues to evolve in MM, so does the likelihood of long-term disease control and the potential for functional cure-a goal that was once a fantasy but is increasingly definable and measurable. A glossary of abbreviations and terms used in this podcast is provided in the appendix for reference.